The role of ACPAs in at-risk individuals: Early targeting of the bone and joints
Author:
- 1 February 2017
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 31 (1) , 53-58
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Pathogenetic insights from the treatment of rheumatoid arthritisThe Lancet, 2017
- Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms – a cohort studyAnnals of the Rheumatic Diseases, 2016
- Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodiesAnnals of the Rheumatic Diseases, 2014
- Loss of metacarpal bone density predicts RA development in recent-onset arthritisRheumatology, 2012
- Brief Report: Airways abnormalities and rheumatoid arthritis–related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?Arthritis & Rheumatism, 2011
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort studyAnnals of the Rheumatic Diseases, 2010
- Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective studyAnnals of the Rheumatic Diseases, 2010
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donorsArthritis & Rheumatism, 2004
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003